代偿期肝硬化患者中采用两种定义时慢加急性肝衰竭的发病率和死亡率
该回顾性队列研究纳入2008至2016年退伍军人健康管理局中80,383例新发代偿期肝硬化患者,中位随访3.35年。按EASL与APASL两种定义分别识别慢加急性肝衰竭(ACLF)事件,比较发病率与28天、90天死亡率。结果显示两种定义间ACLF事件存在显著不一致,EASL单独ACLF多数患者肝功能保留,提示需要更特异的肝脏ACLF标准。
要点
- APASL ACLF发病率为5.7/1000人年(95%CI 5.4-6.0),EASL ACLF为20.1(95%CI 19.5-20.6)。
- APASL ACLF的28天和90天死亡率分别为41.9%和56.1%,EASL ACLF分别为37.6%和50.4%。
- EASL单独ACLF诊断时中位胆红素为2.0 mg/dL(IQR 1.1-4.0),多数患者肝功能保留。
核心结论
- EASL与APASL标准识别的ACLF事件存在显著不一致,EASL单独ACLF多数患者肝功能保留,提示需要更特异的肝脏ACLF标准。
研究设计与样本
- 回顾性队列研究,纳入2008至2016年退伍军人健康管理局中新发代偿期肝硬化患者80,383例,中位随访3.35年,分别按EASL和APASL定义识别首次ACLF事件。
主要发现
- 783例同时符合EASL和APASL ACLF,4,296例仅符合EASL ACLF,574例仅符合APASL ACLF。
- APASL ACLF发病率为5.7/1000人年(95%CI 5.4-6.0),EASL ACLF发病率为20.1/1000人年(95%CI 19.5-20.6)。
- APASL ACLF的28天死亡率为41.9%、90天死亡率为56.1%;EASL ACLF的28天死亡率为37.6%、90天死亡率为50.4%。
- EASL单独ACLF诊断时中位胆红素为2.0 mg/dL(IQR 1.1-4.0)。
- 丙型肝炎或非酒精性脂肪性肝病患者ACLF发病率最低,但短期死亡率最高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The term acute-on-chronic liver failure (ACLF) is intended to identify patients with chronic liver disease who develop rapid deterioration of liver function and high short-term mortality after an acute insult. The two prominent definitions (European Association for the Study of the Liver [EASL] and Asian Pacific Association for the Study of the Liver [APASL]) differ, and existing literature applies to narrow patient groups. We sought to compare ACLF incidence and mortality among a diverse cohort of patients with compensated cirrhosis, using both definitions. This was a retrospective cohort study of patients with incident compensated cirrhosis in the Veterans Health Administration from 2008 to 2016. First ACLF events were identified for each definition. Incidence rates were computed as events per 1,000 person-years, and mortality was calculated at 28 and 90 days. Among 80,383 patients with cirrhosis with 3.35 years median follow-up, 783 developed EASL and APASL ACLF, 4,296 developed EASL ACLF alone, and 574 developed APASL ACLF alone. The incidence rate of APASL ACLF was 5.7 per 1,000 person-years (95% confidence interval [CI]: 5.4-6.0), and the incidence rate of EASL ACLF was 20.1 (95% CI: 19.5-20.6). The 28-day and 90-day mortalities for APASL ACLF were 41.9% and 56.1%, respectively, and were 37.6% and 50.4% for EASL ACLF. The median bilirubin level at diagnosis of EASL-alone ACLF was 2.0 mg/dL (interquartile range: 1.1-4.0). Patients with hepatitis C or nonalcoholic fatty liver disease had among the lowest ACLF incidence rates but had the highest short-term mortality. Conclusion: There is significant discordance in ACLF events by EASL and APASL criteria. The majority of patients with EASL-alone ACLF have preserved liver function, suggesting the need for more liver-specific ACLF criteria.
引用
- Mahmud N, Kaplan DE, Taddei TH, et al. Incidence and Mortality of Acute-on-Chronic Liver Failure Using Two Definitions in Patients with Compensated Cirrhosis. Hepatology. 2019. PMID: 30615211. doi:10.1002/hep.30494
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。